Author: Lilian Zhang

Recon takes an analytical look behind select developments in healthcare

Can doulas help with our maternal health crisis? Promises and obstacles to impact

Lilian Zhang September 18, 2024

About the author: Phiona Nabagereka is currently a high school senior attending the Noble and Greenough School. She spent the summer of 2024 with Recon Strategy as a paid intern assigned a project to research doula integration into clinical care teams. Phiona plans to study biology and statistics in college next year, and is considering a career in healthcare. Significant inequalities in US maternal health today Maternal death rates in the US have more than doubled in the past two decades. Notably, women of color are very overrepresented in

A Kaplan-Meier view of oncology development

Lilian Zhang August 8, 2024

We refresh a prior analysis of two cohorts of oncology development programs: one with first-in-human (FIH) in 2012, and the other with FIH in 2017H2. We use a Kaplan-Meier approach to track whether programs have reached either of two final outcomes: a first approval from FDA, or a discontinuation of development. We find again that programs from commercial pharma reach final outcomes much faster than those from early-stage biotechs, which likely reflects a mix of a higher operational resourcing and efficiency, and more portfolio prioritization rigor. Beyond other specific findings,

Trends and strategy in oncology development

Lilian Zhang May 15, 2023

PDF: Trends and strategy in oncology development Summary We review a sample of oncology programs from the past decade and arrive at the following key findings: The use of expansion cohorts in first-in-human (FIH) studies has grown significantly in the last decade, with an accompanying decrease in separate phase 2 studies Commercial-stage sponsors and early-stage companies backed by established VCs are much more aggressive in discontinuing programs quickly compared to other early-stage companies For drugs that achieve approval, the time from FIH to approval is much shorter for big pharma

Author: Lilian Zhang

Recon takes an analytical look behind select developments in healthcare

Can doulas help with our maternal health crisis? Promises and obstacles to impact

A Kaplan-Meier view of oncology development

Trends and strategy in oncology development

SUBSCRIBE

Categories

Authors

Archives